Ribomic Inc.
Domestic Phase 3 Clinical Trial of Omedaptanib Pegol for Achondroplasia: Announcement of Expanded Investigational Sites
Expansion of domestic Phase 3 clinical trial sites for achondroplasia treatment Umepaptanib pegol to 16 sites nationwide (cumulative 10 sites currently, plan to 16); no impact on fiscal year 2027 performance. Subjects are pediatric patients with rare diseases; new IRB-approved sites expanding.
Key Figures
- Cumulative implementing sites: 10→16 planned (expansion)
- Point in time of expansion: IRB approval already obtained for trial sites
- Impact on FY2027 results: None
AI要約
Overview of performance and trial expansion
This news item reports the expansion of implementing medical institutions for domestic Phase 3 clinical trials of the achondroplasia treatment Umepaptanib pegol. Four new sites have obtained Institutional Review Board approvals, bringing the total implementing sites to 10. The plan is to expand nationwide to 16 sites, strengthening the trial framework in the rare disease area.
Outlook and impact on investors
Expansion of trial sites is expected to accelerate subject enrollment and strengthen nationwide trial operations; however, the impact on the full-year results for the fiscal year ending March 2027 is currently unchanged, with limited short-term financial effects. Development in the rare disease space may contribute to long-term value creation.
株式会社会リボミック
Company overview · Stock price · Financial data · All IR
